KCM
ITCI

Kingdon Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Kingdon Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-40,000
Closed -$1.6M – 152
2015
Q3 		$1.6M Buy
+40,000
New +$1.3M 0.08% 114

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kingdon Capital Management's ITCI Position: Q4 2015 in Review

Kingdon Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2015, closing a stake of 40,000 shares — an estimated $1.6M sold.

Kingdon Capital Management first reported a position in ITCI in Q3 2015 and held it in 1 quarter. The position peaked at $1.6M in Q3 2015. 132 funds tracked by Wall St. Rank hold ITCI as of Q4 2015.

  • Kingdon Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2015 after selling out during the quarter.
  • Kingdon Capital Management sold 40,000 Intra-Cellular Therapies Inc. shares in Q4 2015, an estimated $1.6M.
  • Kingdon Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 1 quarter.
  • Kingdon Capital Management's Intra-Cellular Therapies Inc. position peaked at $1.6M in Q3 2015.
  • 132 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2015.

Based on Kingdon Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.